Aadi bioscience announces poster presentations at the 2024 american society of clinical oncology (asco) genitourinary (gu) cancers symposium

Real-world genomic analysis highlights unmet medical need in gu cancer patients with tsc1/2 inactivating alterations los angeles , jan. 26, 2024 /prnewswire/ -- aadi bioscience, inc. (nasdaq: aadi), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mtor pathway alterations, today announced poster presentations at the 2024 american society of clinical oncology (asco) genitourinary cancers symposium, taking place january 25-27, 2024, in san francisco, ca. abstract and poster presentation details are below: title: "analysis of inactivating alterations in tsc1 and tsc2 in advanced genitourinary (gu) cancers from a real-world patient population in the foundation medicine genomic database" session title: poster session b: urothelial carcinomadate/time: january 26, 2024 – 11:30 – 1:00 pm; 5:45 – 6:45 pm pst presenting author: gopa iyer, mdkey findings: in a large real-world database of patients with advanced cancer, 1,828 (4.0%) of the 46,068 patients with gu cancers had at least one inactivating alteration in tsc1 or tsc2 tsc1 and/or tsc2 inactivating alterations were present in 9.2% of patients with bladder cancer, 6.4% of patients with kidney cancer, and 0.6% of patients with prostate cancer gu cancers with tsc1 and/or tsc2 inactivating alterations were frequently microsatellite stable and of low tumor mutational burden (tmb) the precision 1 study (nct05103358) is currently enrolling patients with solid tumors harboring tsc1 and/or tsc2 inactivating alterations aadi is also presenting an encore trials-in-progress (tip) poster from the ongoing precision 1 study.
AADI Ratings Summary
AADI Quant Ranking